Share Email Print
cover

Proceedings Paper

Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients
Author(s): Xiaosong Li; Mark F. Naylor; Robert E. Nordquist; T. Kent Teague; C. Anthony Howard; Cynthia Murray; Wei R. Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

In Situ Photoimmunotherapy (ISPI), a newly developed modality for cancer therapy, has been shown to be able to modulate the body's own immune response. This clinical trial was designed to evaluate the safety and therapeutic effect of ISPI, using imiquimod as its immunoadjuvant for metastatic melanoma patients. ISPI consisted of three main components applied directly to the cutaneous metastases: 1) local application of topical imiquimod; 2) injection of indocyanine green; and 3) an 805 nm laser for local irradiation. All patients completed at least one cycle of treatment. All the patients completed at least one cycle of treatments; one patient received 6 cycles. The most common adverse effects were rash, pruritus, pain, fatigue and anorexia. Fever, chills, vomiting and cellulitis were relative rare. No grade 4 toxicity was observed. Complete Response (CR) was observed in 6 patients. Median overall survival of the 11 evaluated patients was 12.2 months. Six of the eleven patients were still alive at the time of this report. Treatment of ISPI using imiquimod is safe and well tolerant. Our preliminary clinical results suggest that this new method can be a promising modality for metastatic melanoma.

Paper Details

Date Published: 25 February 2010
PDF: 8 pages
Proc. SPIE 7565, Biophotonics and Immune Responses V, 756506 (25 February 2010); doi: 10.1117/12.843260
Show Author Affiliations
Xiaosong Li, Univ. of Central Oklahoma (United States)
Chinese PLA General Hospital (China)
Mark F. Naylor, Univ of Oklahoma College of Medicine (United States)
Robert E. Nordquist, Wound Healing of Oklahoma (United States)
T. Kent Teague, Univ of Oklahoma College of Medicine (United States)
Univ. of Oklahoma College of Pharmacy (United States)
Oklahoma State Univ. Ctr. for Health Sciences (United States)
C. Anthony Howard, Univ of Oklahoma College of Medicine (United States)
Cynthia Murray, Univ. of Central Oklahoma (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 7565:
Biophotonics and Immune Responses V
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top